Title Image

SPONSORS

ADVENT is a non-promotional global medical education program by Sanofi and Regeneron, designed to engage healthcare professionals (HCPs) and advance the understanding of the role of type 2 inflammation across several diseases within dermatology, pulmonology, rhinology, and gastroenterology. Offering a wide variety of face-to-face and digital opportunities, the ADVENT program aims to provide HCPs with high-quality, fair-balanced, and continuous education to advance clinical management and improve patient care. At its core, the objectives of the ADVENT program are to educate on type 2 inflammation, with a focus on advancing understanding of pathophysiology and highlighting the significant burden suffered by patients, families, and caregivers. The ADVENT program prioritizes the exploration and dissemination of evolving data on new therapeutic approaches to management and prompts understanding of the multidisciplinary implications and cumulative burden associated with type 2 inflammatory diseases, including atopic dermatitis, prurigo nodularis, chronic spontaneous urticaria, and bullous pemphigoid.

The name ADVENT, formed by combining ‘AD’ (atopic dermatitis & dermatology), ‘VENT’ (ventilation = pulmonology), and ‘ENT’ (rhinology), signifies a novel and innovative approach to medical education, which has historically relied on traditional, short-term IME/CME programs. The ADVENT program was designed to disrupt these conventional formats, offering a continuously evolving curriculum of varied digital resources and in-person experiences conducive for diverse learning styles, all of which are developed in collaboration with over 100 global medical experts.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Argenx Commitment to Patients

Each day at argenx, we are motivated to pursue a better tomorrow alongside patients. We aim to do this through partnership because we know that “together we are better”. As your ally, we pioneer innovations to advance the understanding of rare diseases; we want to deliver immunology treatments to patients worldwide.

We listen to patients, supporters and advocacy communities; we hear your stories and share your determination. We integrate your aspirations into how we innovate, how we conduct research and design trials, and how we can support you in the daily struggles you face living with a rare disease.

There is a common purpose across argenx that is driven by your resilience and we welcome this opportunity to be with you on this journey.

At UCB, we believe everyone deserves to live the best life that they can – as free as possible from the challenges of disease. We develop solutions across neurology, immunology, and other areas where our expertise, innovation, and ambition align with the needs of those who live with severe diseases.

We are curious and collaborative, driven to create valuable solutions and improve the health and wellbeing of our people, our communities, and the planet. We seek out tools, technologies, and partners that help us respond to patient needs with purposeful innovations that make a truly meaningful impact.